# Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

> **NCT04391985** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 113 (actual)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF plus (OBV/PTV/r) plus RBV

## Key facts

- **NCT ID:** NCT04391985
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2017-10-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391985, "Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04391985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*